How ARA-290 Works: Mechanism and Pharmacology
How ARA-290 works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.
- Class
- EPO-derived peptide
- FDA status
- Not approved
- research chemical
- Routes studied
- intravenous; subcutaneous, self-administered; intraperitoneal
- Half-life
- ~2 min
- plasma (route not stated in abstract), in people · Pharmacology & therapeutics 2015, PMID 25728128
How long it acts
Half-life values from FDA labels and published studies, by route. Animal values are labelled and do not describe people.
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| plasma (route not stated in abstract) | ~2 min | People | Pharmacology & therapeutics 2015, PMID 25728128 |
The receptor it targets
ARA 290 is described as a peptide designed to activate the innate repair receptor, which the authors say arrests injury and initiates protection, anti-inflammation and healing.[2]
The innate repair receptor is a heteromer of the erythropoietin receptor and the beta-common receptor (CD131), as distinct from the EPOR homodimer that drives red cell production.[3]
The review explains that the innate repair receptor is typically not expressed in normal tissue but is induced rapidly by injury or inflammation.[1]
Evidence that the receptor matters (animals)
In mice lacking the beta-common receptor, ARA290 had no effect on pain behaviour, while it worked in normal mice, which supports receptor dependence in this mouse model.[4]
In activated mouse macrophages, cibinetide's anti-inflammatory effect depended on CD131 and JAK2 and ran through inhibition of the NF-kB subunit p65.[3]
In rats with autoimmune encephalomyelitis, ARA290 shifted T-cell polarisation towards Th2 and regulatory T cells and away from Th1 and Th17 cells.[5]
What happens in people
In a phase 2b sarcoidosis trial, cibinetide increased small nerve fibre abundance in the cornea and skin, which the authors called consistent with a disease modifying effect.[6]
In healthy volunteers given ARA290, neural responses to happy faces were lower in the fusiform gyrus of the brain.[7]
Common questions
How long does ARA-290 act in the body?
The half-life values we found are ~2 min (plasma (route not stated in abstract)). A half-life is how long the amount in the body takes to fall by half; it is not the same as how long an effect lasts.
How does ARA 290 work?
It is designed to activate the innate repair receptor, a receptor complex that mediates tissue protection.[8]
More on ARA-290
Sources
- 1Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
- 2Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
- 3Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis.Scientific reports · 2017PMID 29026145Accessed 2 Oct 2026
- 4ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026
- 5Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat.Journal of neuroimmunology · 2014PMID 24518674Accessed 2 Oct 2026
- 6Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
- 7Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015PMID 26431906Accessed 2 Oct 2026
- 8ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
Found an error? Report a correction.